Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Dividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ani Pharmaceuticals (ANIP) Amortizatization of Intangibles: 2023-2025

Historic Amortizatization of Intangibles for Ani Pharmaceuticals (ANIP) over the last 3 years, with Sep 2025 value amounting to $358,000.

  • Ani Pharmaceuticals' Amortizatization of Intangibles fell 85.53% to $358,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $11.6 million, marking a year-over-year increase of 221.19%. This contributed to the annual value of $13.6 million for FY2024, which is 971.63% up from last year.
  • Ani Pharmaceuticals' Amortizatization of Intangibles amounted to $358,000 in Q3 2025, which was down 9.14% from $394,000 recorded in Q2 2025.
  • Ani Pharmaceuticals' Amortizatization of Intangibles' 5-year high stood at $10.4 million during Q4 2024, with a 5-year trough of $61,000 in Q2 2023.
  • For the 3-year period, Ani Pharmaceuticals' Amortizatization of Intangibles averaged around $1.6 million, with its median value being $387,500 (2023).
  • Per our database at Business Quant, Ani Pharmaceuticals' Amortizatization of Intangibles soared by 2,623.10% in 2024 and then plummeted by 85.53% in 2025.
  • Over the past 3 years, Ani Pharmaceuticals' Amortizatization of Intangibles (Quarterly) stood at $381,000 in 2023, then spiked by 2,623.10% to $10.4 million in 2024, then tumbled by 85.53% to $358,000 in 2025.
  • Its Amortizatization of Intangibles was $358,000 in Q3 2025, compared to $394,000 in Q2 2025 and $452,000 in Q1 2025.